Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 11, 2022

US Population–Level Impact of SGLT2 Inhibitors for HFpEF

JAMA Cardiology


Additional Info

JAMA Cardiology
Population-Level Implications of Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure With Preserved Ejection Fraction in the US
JAMA Cardiol 2022 Nov 05;[EPub Ahead of Print], KM Talha, J Butler, SJ Greene, R Aggarwal, SD Anker, BL Claggett, SD Solomon, JJV McMurray, M Vaduganathan, GC Fonarow

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading